Market open

United Therapeutics/$UTHR

14:30

22:10

05:45

13:25

21:00

1D1W1MYTD1Y5YMAX

About United Therapeutics

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Ticker

$UTHR

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Silver Spring, United States

Employees

1,168

Website

www.unither.com

UTHR Metrics

BasicAdvanced

$16B

16.04 $22.73

0.57 -

Price and volume

Market cap

$16B

Beta

0.57

52-week high

$403.35

52-week low

$208.62

Average daily volume

280K

Financial strength

Current ratio

4.58

Quick ratio

4.2

Total debt to equity

6.556

Interest coverage (TTM)

26.86%

Management effectiveness

Return on assets (TTM)

11.89%

Return on equity (TTM)

18.81%

Valuation

Price to earnings (TTM)

16.043

Price to revenue (TTM)

6.054

Price to book

2.67

Price to tangible book (TTM)

2.72

Price to free cash flow (TTM)

18.578

Growth

Revenue change (TTM)

25.04%

Earnings per share change (TTM)

25.15%

3-year revenue growth (CAGR)

18.53%

3-year earnings per share growth (CAGR)

31.86%

What the Analysts think about UTHR

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for United Therapeutics stock.

UTHR Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

UTHR Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

UTHR News

AllArticlesVideos

The Zen Ten - My Top Picks For 2025

Seeking Alpha·2 weeks ago

United Therapeutics: Competitive Advantages At Such Cheap Multiples Scream Buy

Seeking Alpha·2 months ago

United Therapeutics Expands Into Organ Transplants, But Tyvaso's Legal Battles Loom

Seeking Alpha·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $UTHR

$

Capital at risk

Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for United Therapeutics stock?

United Therapeutics (UTHR) has a market cap of $16B as of January 15, 2025.

What is the P/E ratio for United Therapeutics stock?

The price to earnings (P/E) ratio for United Therapeutics (UTHR) stock is 16.04 as of January 15, 2025.

Does United Therapeutics stock pay dividends?

No, United Therapeutics (UTHR) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next United Therapeutics dividend payment date?

United Therapeutics (UTHR) stock does not pay dividends to its shareholders.

What is the beta indicator for United Therapeutics?

United Therapeutics (UTHR) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.